Remove Clinical Trials Remove Events Remove History Remove Treatment
article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada.

article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

Scientists are hopeful that psychedelics might have more of a curative effect when it comes to mental health than many existing treatment options; meaning that unlike most psychiatric medications, psychedelics may be able to prompt long-term changes to our mental state with only a few doses. Are psychedelics safe? Classical psychedelics .

History 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Cannabis Law Report

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

article thumbnail

Cannabis laws in Japan: Is weed legal?

The Cannigma

However, the country has a history of cannabis art dating back millenia , and scholars believe that the plant was used for centuries as a textile and for use in traditional Shinto ceremonies. CBD has become especially trendy in Tokyo, where CBD shops and cafes allow for the on-site consumption of CBD in edibles and topical treatments.

Law 137
article thumbnail

Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021

Cannabis Law Report

(NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S.

article thumbnail

Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference

Cannabis Law Report

The Liver Meeting, which takes place virtually on November 12 – 15, 2021, brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.

article thumbnail

Press Release: MindMed Engages in Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

Cannabis Law Report

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. Securities and Exchange Commission on EDGAR at www.sec.gov.